Iranian mRNA vaccine to start clinical trial

March 12, 2022 - 17:36

TEHRAN – The Iranian mRNA vaccine for coronavirus has received permission from the Food and Drug Administration to enter phase one of the human trials, said a member of the scientific committee of the National Headquarters for Coronavirus Control.

The Iranian mRNA vaccine, which is similar to Pfizer, is being developed by a knowledge-based company, IRNA quoted Mostafa Ghanei as saying on Saturday.

Messenger RNA is a type of RNA that is necessary for protein production. In cells, mRNA uses the information in genes to create a blueprint for making proteins. Once cells finish making a protein, they quickly break down the mRNA. mRNA from vaccines does not enter the nucleus and does not alter DNA.

Iran is among the few countries with all vaccine production platforms.

Antibodies help protect the body against infection by recognizing individual viruses or other pathogens, attaching to them, and marking the pathogens for destruction. 

Once produced, antibodies remain in the body, even after the body has rid itself of the pathogen, so that the immune system can quickly respond if exposed again. 

If a person is exposed to a virus after receiving mRNA vaccination for it, antibodies can quickly recognize it, attach to it, and mark it for destruction before it can cause serious illness.

Domestically-made vaccines

Iran is the sixth country in the world and the first country in West Asia to gain the ability to produce the Coronavirus vaccine.

Considering that five coronavirus vaccines have so far been produced domestically, Mohammad Reza Shanehsaz, the former head of the Food and Drug Administration, said in June 2021 that Iran is one of the few countries that has all vaccine production platforms.

A total of 21 knowledge-based companies are operating to produce 50 million doses of vaccine monthly and 600 million doses annually, IRNA quoted Bahram Daraei as saying on March 9.

On February 7, ISNA reported that two domestic companies have completed the animal phase of a clinical study to develop vaccines against the Omicron strain.

Made by researchers at the Headquarters for Executing the Order of the Imam, COVIRAN BARKAT was unveiled on December 29, 2020, and received the license for public use on June 14.
COVIRAN is the first vaccine in West Asia that is in the process of global registration.

Developed by the Razi Vaccine and Serum Research Institute, Razi Cov Pars is the second Iranian-made vaccine that started the clinical trial on February 27.

Moreover, the Iranian-Australian Spikogen vaccine and Pastu Covac, developed jointly by the Pasteur Institute of Iran and Cuba's Finlay Vaccine Institute, are other vaccines, which have received the emergency use license.

FB/MG

 

Leave a Comment

2 + 11 =